Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
Open Access
- 30 March 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 15
Abstract
Multiple sclerosis (MS)-related inflammation can be divided into lesional activity, mediated by immune cells migrating from the periphery to the central nervous system (CNS) and non-lesional activity, mediated by inflammation compartmentalized to CNS tissue. Lesional inflammatory activity, reflected by contrast-enhancing lesions (CELs) on the magnetic resonance imaging (MRI), is effectively inhibited by current disease modifying therapies (DMTs). While, the effect of DMTs on non-lesional inflammatory activity is currently unknown. Reliable and simultaneous measurements of both lesional and non-lesional MS activity is necessary to understand their contribution to CNS tissue destruction in individual patients. We previously demonstrated that CNS compartmentalized inflammation can be measured by combined quantification of cerebrospinal fluid (CSF) immune cells and cell-specific soluble markers. The goal of this study is to develop and validate a CSF-biomarker-based molecular surrogate of MS lesional activity. The training cohort was dichotomized into active (CELs > 1 or clinical relapse) and inactive lesional activity (no CELs or relapse) groups. Matched CSF and serum samples were analyzed for 20 inflammatory and axonal damage biomarkers in a blinded fashion. Only the findings from the training cohort with less than 0.1% probability of false positive (i.e.,p< 0.001) were validated in an independent validation cohort. MS patients with lesional activity have elevated IL-12p40, CHI3L1, TNFα, TNFβ, and IL-10, with the first two having the strongest effects and validated statistically-significant association with lesional activity in an independent validation cohort. Marker of axonal damage, neurofilament light (NfL), measured in CSF (cNfL) was also significantly elevated in MS patients with active lesions. NfL measured in serum (sNfL) did not differentiate the two MS subgroups with pre-determined significance, (p= 0.0690) even though cCSF and sNfL correlated (Rho = 0.66,p< 0.0001). Finally, the additive model of IL12p40 and CHI3L1 outperforms any biomarker discretely. IL12p40 and CHI3L1, released predominantly by immune cells of myeloid lineage are reproducibly the best CSF biomarkers of MS lesional activity. The residuals from the IL12p40/CHI3L1-cNfL correlations may identify MS patients with more destructive inflammation or contributing neurodegeneration.Keywords
This publication has 45 references indexed in Scilit:
- Initial Immunopathogenesis of Multiple Sclerosis: Innate Immune ResponseJournal of Immunology Research, 2013
- Neurofilaments as biomarkers in multiple sclerosisMultiple Sclerosis Journal, 2012
- Isolation and detection of single molecules on paramagnetic beads using sequential fluid flows in microfabricated polymer array assembliesLab on a Chip, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrationsNature Biotechnology, 2010
- In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseasesJournal of Neuroinflammation, 2010
- Multiple sclerosis: Distribution of inflammatory cells in newly forming lesionsAnnals of Neurology, 2009
- The relation between inflammation and neurodegeneration in multiple sclerosis brainsBrain, 2009
- Immunopathology of secondary‐progressive multiple sclerosisAnnals of Neurology, 2001
- Rating neurologic impairment in multiple sclerosisNeurology, 1983